Myles Ba Finlay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Myles Ba Finlay has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Marian Wilson
College of Nursing, Washington State University, Spokane, USA
2 shared publications - Dedra Buchwald
Department of Neurological Surgery, University of Washington, Seattle, WA, United States
1 shared publication - Devon A. Hansen
Sleep and Performance Research Center, Washington State University, Spokane, WA, USA
1 shared publication Devon A. PhD Hansen
Myles Finlay, BA, RPSGT, Julie A. Erwin, MS, RPSGT, Lillian Skeiky, MS, Devon A. Hansen, PhD, LMHC, Matthew E. Layton, MD, PhD, Hans P. A. Van Dongen, PhD, and Marian Wilson, PhD, MPH, RN-BC, Sleep and Performance Research Center, Washington State University, Spokane
1 shared publication- Diane Joyce Cook
Washington State University
1 shared publication - Elie Gottlieb
Sleep.ai, Carlsbad, CA, United States
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e73969
Assessing Night-to-Night Sleep Variability as a Hallmark of Chronic Insomnia Using Longitudinal, Contactless, Mobile Sleep Monitoring: Prospective Cohort Study
Background: Chronic insomnia affects more than 30% of US adults, is more prevalent in women and older adults, and is strongly associated with poor mental and physical health outcomes. Poor sleep quality and intraindividual variability of sleep are recognized to be key characteristics of chronic insomnia, but longitudinal assessment of sleep is largely subjective, with no objective characterization of sleep patterns and intraindividual variability over extended periods. Objective, ecologically valid longitudinal sleep measurements are needed to help identify and manage insomnia in both clinical and population settings. Consumer sleep technologies offer a possible solution, but their clinical utility remains relatively unexplored. Objective: We aimed to evaluate the utility of a contactless, radio frequency–based device by demonstrating its ability to objectively characterize sleep in individuals with insomnia over an extended observation period in a naturalistic home environment. Methods: Eighty-three participants meeting criteria for chronic insomnia and 29 healthy good-sleeper controls underwent 8 consecutive weeks of home-based sleep monitoring using an objective, contactless, radio frequency–based sleep monitoring device. Sleep efficiency, sleep latency, intermittent wakefulness, time in bed, and total sleep time were objectively quantified as daily means and SDs. Results: Compared to healthy controls, individuals with chronic insomnia exhibited reduced sleep efficiency, increased sleep latency, and increased intermittent wakefulness. They also demonstrated significantly higher night-to-night variability (SDs) in sleep efficiency, sleep latency, and intermittent wakefulness than good-sleeper controls (all P <.001). Conclusions: In the longest known objective characterization of sleep among individuals with chronic insomnia, we show that a radio frequency–based, contactless sleep monitoring device deployed in the participants’ typical sleep environments accurately distinguished healthy good sleepers from those with insomnia. Importantly, we show that persistent night-to-night variability in objective sleep measures is a hallmark of chronic insomnia.
- 18 March 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e73969
Open AccessAssessing Night-to-Night Sleep Variability as a Hallmark of Chronic Insomnia Using Longitudinal, Contactless, Mobile Sleep Monitoring: Prospective Cohort Study
Background: Chronic insomnia affects more than 30% of US adults, is more prevalent in women and older adults, and is strongly associated with poor mental and physical health outcomes. Poor sleep quality and intraindividual variability of sleep are recognized to be key characteristics of chronic insomnia, but longitudinal assessment of sleep is largely subjective, with no objective characterization of sleep patterns and intraindividual variability over extended periods. Objective, ecologically valid longitudinal sleep measurements are needed to help identify and manage insomnia in both clinical and population settings. Consumer sleep technologies offer a possible solution, but their clinical utility remains relatively unexplored. Objective: We aimed to evaluate the utility of a contactless, radio frequency–based device by demonstrating its ability to objectively characterize sleep in individuals with insomnia over an extended observation period in a naturalistic home environment. Methods: Eighty-three participants meeting criteria for chronic insomnia and 29 healthy good-sleeper controls underwent 8 consecutive weeks of home-based sleep monitoring using an objective, contactless, radio frequency–based sleep monitoring device. Sleep efficiency, sleep latency, intermittent wakefulness, time in bed, and total sleep time were objectively quantified as daily means and SDs. Results: Compared to healthy controls, individuals with chronic insomnia exhibited reduced sleep efficiency, increased sleep latency, and increased intermittent wakefulness. They also demonstrated significantly higher night-to-night variability (SDs) in sleep efficiency, sleep latency, and intermittent wakefulness than good-sleeper controls (all P <.001). Conclusions: In the longest known objective characterization of sleep among individuals with chronic insomnia, we show that a radio frequency–based, contactless sleep monitoring device deployed in the participants’ typical sleep environments accurately distinguished healthy good sleepers from those with insomnia. Importantly, we show that persistent night-to-night variability in objective sleep measures is a hallmark of chronic insomnia.
- 28 September 2023
- Published by Wolters Kluwer Health in Journal of Addictions Nursing
- Vol. 34 (4) , E180-E188
Nighttime Sleep and Respiratory Disturbances in Individuals Receiving Methadone to Treat Opioid Use Disorder
Opioids are a leading cause of drug overdose deaths in the United States. Methadone used as medication for opioid use disorder (MOUD) reduces drug cravings and promotes abstinence. However, individuals in methadone-based MOUD treatment commonly report subjective sleep complaints and are at risk for respiratory depression from opioids. We investigated nighttime sleep and respiratory function in eight individuals (six women, two men; ages 31–68 years) in their first 90 days of methadone-based MOUD treatment. Participants underwent overnight cardiorespiratory polysomnography. Sleep and respiratory variables were characterized with descriptive statistics for comparison to reference data from similarly aged healthy adults. Although participants spent 8.1 ± 0.3 hours (mean ± SD) in bed, their total sleep time was only 6.8 ± 1.3 hours. They exhibited longer sleep latency and intermittent wakefulness. Sleep structure was irregular, with disrupted sleep cycles. Participants also displayed a decreased amount of N1 sleep and an increased amount of N3 sleep, compared with reference data. Participants showed respiratory depression, with an average apnea–hypopnea index of 16.5 ± 8.9 events per hour. Central sleep apneas comprised 69.1% ± 20.9% of the respiratory events. A Cheyne–Stokes-like breathing pattern, consisting of 30-second cycles of three central sleep apneas, was observed in 75% of participants. Our results suggest that individuals early in methadone-based MOUD treatment experience disordered sleep and respiratory disturbances. Such nighttime physiological changes may have serious long-term health consequences and contribute to unintended overdose rates. Identifying and treating MOUD individuals with sleep apnea could reduce risk of death.
- 28 September 2023
- Published by Wolters Kluwer Health in Journal of Addictions Nursing
- Vol. 34 (4) , E180-E188
Nighttime Sleep and Respiratory Disturbances in Individuals Receiving Methadone to Treat Opioid Use Disorder
Opioids are a leading cause of drug overdose deaths in the United States. Methadone used as medication for opioid use disorder (MOUD) reduces drug cravings and promotes abstinence. However, individuals in methadone-based MOUD treatment commonly report subjective sleep complaints and are at risk for respiratory depression from opioids. We investigated nighttime sleep and respiratory function in eight individuals (six women, two men; ages 31–68 years) in their first 90 days of methadone-based MOUD treatment. Participants underwent overnight cardiorespiratory polysomnography. Sleep and respiratory variables were characterized with descriptive statistics for comparison to reference data from similarly aged healthy adults. Although participants spent 8.1 ± 0.3 hours (mean ± SD) in bed, their total sleep time was only 6.8 ± 1.3 hours. They exhibited longer sleep latency and intermittent wakefulness. Sleep structure was irregular, with disrupted sleep cycles. Participants also displayed a decreased amount of N1 sleep and an increased amount of N3 sleep, compared with reference data. Participants showed respiratory depression, with an average apnea–hypopnea index of 16.5 ± 8.9 events per hour. Central sleep apneas comprised 69.1% ± 20.9% of the respiratory events. A Cheyne–Stokes-like breathing pattern, consisting of 30-second cycles of three central sleep apneas, was observed in 75% of participants. Our results suggest that individuals early in methadone-based MOUD treatment experience disordered sleep and respiratory disturbances. Such nighttime physiological changes may have serious long-term health consequences and contribute to unintended overdose rates. Identifying and treating MOUD individuals with sleep apnea could reduce risk of death.
- Open Access
- 27 September 2022
- Published by Elsevier in Pain Management Nursing
- Vol. 24 (1) , 4-11
Piloting Smart Home Sensors to Detect Overnight Respiratory and Withdrawal Symptoms in Adults Prescribed Opioids
- 27 September 2022
- Published by Elsevier in Pain Management Nursing
- Vol. 24 (1) , 4-11
Open AccessPiloting Smart Home Sensors to Detect Overnight Respiratory and Withdrawal Symptoms in Adults Prescribed Opioids